Information:
Fel:
ID
17214
Beskrivning
ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity; ODM derived from: https://clinicaltrials.gov/show/NCT00263965
Länk
https://clinicaltrials.gov/show/NCT00263965
Nyckelord
Versioner (1)
- 2016-09-01 2016-09-01 -
Uppladdad den
1 september 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Type 2 Diabetes NCT00263965
Eligibility Type 2 Diabetes NCT00263965
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes NCT00263965
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Informed consent
Item
provision of a written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
men or women who are 30-70 years of age
boolean
C0001779 (UMLS CUI [1])
female patients: postmenopausal, hysterectomized
Item
female patients: postmenopausal, hysterectomized
boolean
C0232970 (UMLS CUI [1])
C0020699 (UMLS CUI [2])
C0020699 (UMLS CUI [2])
type 2 diabetes
Item
diagnosed with type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Treatment with diet alone or with a single oral antidiabetic agent or two oral antidiabetic agents
Item
treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
boolean
C0011878 (UMLS CUI [1])
C0359086 (UMLS CUI [2])
C0359086 (UMLS CUI [2])
type 1 diabetes
Item
type 1 diabetes
boolean
C0011854 (UMLS CUI [1])
NYHA
Item
new york heart association heart failure class iii or iv
boolean
C1275491 (UMLS CUI [1])
Insulin
Item
treatment with chronic insulin
boolean
C0021641 (UMLS CUI [1])
hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist, fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor
Item
history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin)
boolean
C0020517 (UMLS CUI [1,1])
C1257987 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0033228 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0025598 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0360714 (UMLS CUI [4,2])
C1257987 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0033228 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0025598 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0360714 (UMLS CUI [4,2])
drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia
Item
history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
boolean
C0410220 (UMLS CUI [1])
C0151576 (UMLS CUI [2,1])
C0458082 (UMLS CUI [2,2])
C0428321 (UMLS CUI [3])
C0027947 (UMLS CUI [4])
C0151576 (UMLS CUI [2,1])
C0458082 (UMLS CUI [2,2])
C0428321 (UMLS CUI [3])
C0027947 (UMLS CUI [4])
creatinine
Item
creatinine levels above twice the normal range
boolean
C0201975 (UMLS CUI [1])
creatine kinase
Item
creatine kinase above 3 times the upper limit of normal
boolean
C0201973 (UMLS CUI [1])
investigational drug
Item
received any investigational product in other clinical studies within 12 weeks
boolean
C0013230 (UMLS CUI [1])
Comorbidity compromising patient safety or successful participation in clinical study
Item
any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])